CA AB2760

Requires prescribers to offer a prescription for naloxone hydrochloride or another FDA-approved opioid reversal drug when patients are prescribed 90+ morphine milligram equivalents daily, opioids concurrent with benzodiazepines, or have increased overdose risk including history of overdose or substance use disorder

Mandates prescribers provide education on overdose prevention and naloxone use to patients receiving opioid prescriptions meeting the above conditions, and to at least one person designated by the patient or the patient's parent/guardian if a minor

Exempts prescribers from these requirements when treating inmates or youth under the jurisdiction of the Department of Corrections and Rehabilitation or Division of Juvenile Justice

Subjects prescribers who violate these provisions to referral to their licensing board for administrative sanctions, but creates no private right of action and does not limit liability for negligent failure to diagnose or treat

Approved by Governor September 10, 2018 and filed with Secretary of State the same date